Pacira BioSciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PCRX, updated each market day.
PCRX AI Sentiment
AI sees no strong directional signal for Pacira BioSciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Pacira BioSciences, Inc. Common Stock
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Sector
Exchange
Market Cap
$925,856,651
Cap Tier
Employees
829
Headquarters
BRISBANE, CA
Listed Since
Feb. 3, 2011
Website
PCRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PCRX Volatility
Pacira BioSciences, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
